Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genetic Screens

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

Toxicity Testing in Animals

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

In vitro Mutagenesis

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular Hybrids of Serum Albumin and Cobalt Phthalocyanine for Asymmetric Oxidation of C=C and C-H Bonds.

ACS applied materials & interfaces·2026

Same author

Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern.

Archives of toxicology·2026

Same author

Response to Mr. DiNardo's "Letter to the Editor: Comprehensive review of octocrylene toxicology data and human exposure assessment for personal care products".

Critical reviews in toxicology·2026

Same author

Quantitative evaluation of genotoxicity data for risk assessment and regulatory decision-making: Time for a paradigm shift.

Environment international·2026

Same author

Comprehensive review of octocrylene toxicology data and human exposure assessment for personal care products.

Critical reviews in toxicology·2026

Same author

An evaluation of the utility of blood concentration of somatic mutagens to inform germ cell mutagenic hazard.

Regulatory toxicology and pharmacology : RTP·2025

Search research articles

Related Experiment Video

Updated: Jun 9, 2026

The Lambda Select cII Mutation Detection System

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

New and emerging technologies for genetic toxicity testing.

Anthony M Lynch¹, Jennifer C Sasaki, Rosalie Elespuru

¹GlaxoSmithKline R&D, Ware, Hertfordshire, United Kingdom.

Environmental and Molecular Mutagenesis

|August 27, 2010

Summary

This summary is machine-generated.

New technologies in genetic toxicology testing are reviewed to improve hazard and risk assessment. These advancements aim to refine follow-up testing for positive results in standard in vitro genetic toxicity assays, enhancing human risk evaluations.

More Related Videos

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Comprehensive Assessment of Germline Chemical Toxicity Using the Nematode Caenorhabditis elegans

Comprehensive Assessment of Germline Chemical Toxicity Using the Nematode Caenorhabditis elegans

Published on: February 22, 2015

Related Experiment Videos

Last Updated: Jun 9, 2026

The Lambda Select cII Mutation Detection System

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Comprehensive Assessment of Germline Chemical Toxicity Using the Nematode Caenorhabditis elegans

Comprehensive Assessment of Germline Chemical Toxicity Using the Nematode Caenorhabditis elegans

Published on: February 22, 2015

Area of Science:

Toxicology
Genetics
Biotechnology

Background:

The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) established a workgroup to assess the state-of-the-art in genetic toxicology testing.
The workgroup focused on identifying novel technologies to enhance genotoxicity testing and in vivo hazard/risk assessment.
A workshop in May 2008 discussed mature, maturing, and emerging technologies in the field.

Purpose of the Study:

To review and identify promising new technologies in genetic toxicology.
To evaluate how these technologies can improve genotoxicity testing and risk assessment.
To align new technologies with the objectives of In Vitro Genetic Toxicity (IVGT) testing, particularly for follow-up assessments.

Main Methods:

Compilation of abstracts from the New and Emerging Technologies Workshop.
Inclusion of additional technologies considered by the workgroup.
Analysis of each technology's strengths, weaknesses, opportunities, and threats (SWOT).

Main Results:

An overview of various new and emerging technologies in genetic toxicology was presented.
Technologies were assessed for their potential to meet IVGT objectives.
Consideration was given to using new methods for follow-up testing of positive results in standard IVGT assays.

Conclusions:

Emerging technologies offer potential to improve the weight of evidence and mechanistic understanding in genotoxicity testing.
These advancements can lead to more refined genetic toxicity risk assessments for humans.
The integration of new strategies is crucial for advancing the field of genetic toxicology.